Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients

Emmanouil Spanoudakis (1) , Ioanna Bazdiara (1) , Ioannis Kotsianidis (1) , Dimitrios Margaritis (1) , Aggelos Goutzouvelidis (1) , Anna Christoforidou (1) , Costas Tsatalas (1) , George Bourikas (1)

1 Department of Haematology

Ph-negative chronic myeloproliferative disorders (PhcMPD) are treated according to the estimated vascular risk. The recent discovery of V617F point mutation of the JAK2 kinase, which frequently occurs in these diseases, has not changed their management so far. However, emerging data tend to support a prothrombotic role for the mutation, along with a better response of JAK2V617F mutated patients to hydroxyurea treatment. Our data further support this notion.

Mots clés: PhcMPD; JAK2V617F; Hydroxyurea

Emmanouil Spanoudakis, Ioanna Bazdiara, Ioannis Kotsianidis, Dimitrios Margaritis, Aggelos Goutzouvelidis, et al.. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients. Annals of Hematology, 2008, 88 (7), pp.629-632. ⟨10.1007/s00277-008-0650-1⟩. ⟨hal-00535010⟩